TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancer

samuraciclib (CT7001) - Carrick Therap

Kisqali (ribociclib) - Novartis

vepdegestrant (ARV-471) - Arvinas, Pfizer

Verzenio (abemaciclib) - Eli Lilly

fulvestrant - Generic mfg.

https://atgproductions.net/atgclients/sabcs/2023_SABCS_Abstract_Report-12-1-23_Compressed.pdf

Claudine Isaacs1; Katarzyna Jerzak2; John Hilton3; José Luiz Miranda Guimarães4; Rachel Layman5; Dongrui Lu6; Gary Mo7; Anna Maria Calella8; Olga Valota8; Sibyl Anderson9; Cynthia Ma10

Nov 4, 2023